PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29486473-11	2018	JNK inhibitor SP600125 prevented PA-mediated increase of Nox4, IL-8, IL-6 and iTG.	pyrazolanthrone	14-22	interleukin 6	Mus musculus	69-73	
29890414-7	2018	The NF-kappaB inhibitor JSH-23 and JNK-specific inhibitor SP600125 significantly decreased NO production and IL-6 release in LPS-stimulated BV2 cells, respectively.	pyrazolanthrone	58-66	interleukin 6	Mus musculus	109-113	
29926065-10	2018	The inhibitors of p38 (SB202190) and JNK (SP600125) could reduce IL-6 and TNF-alpha mRNA expression that was induced by LPS.	pyrazolanthrone	42-50	interleukin 6	Mus musculus	65-69	
31849448-11	2019	In vitro, LPS-induced production of TNF-alpha and IL-6 and gene expression of TNF-alpha, IL-6, IL-1beta, and COX-2 could be inhibited by the pretreatment with C66 and SP600125.	pyrazolanthrone	167-175	interleukin 6	Mus musculus	89-93	
22488045-10	2012	Selective blocking of the MAPK pathways with p38 inhibitor SB203580 significantly decreased arsenic-induced HO-1 and VEGF expression, while JNKs inhibitor SP600125 increased IL-6 expression.	pyrazolanthrone	155-163	interleukin 6	Mus musculus	174-178	
28672025-7	2017	Phosphorylated JNK increased significantly compared to the control after BV2 cells were treated with IL-6 for 1 h. Pretreatment with SP600125 attenuated the up-regulation of IRP1 and DMT1 and down-regulation of FPN1 (compared to IL-6-treated group).	pyrazolanthrone	133-141	interleukin 6	Mus musculus	101-105	
28672025-7	2017	Phosphorylated JNK increased significantly compared to the control after BV2 cells were treated with IL-6 for 1 h. Pretreatment with SP600125 attenuated the up-regulation of IRP1 and DMT1 and down-regulation of FPN1 (compared to IL-6-treated group).	pyrazolanthrone	133-141	interleukin 6	Mus musculus	229-233	
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	interleukin 6	Mus musculus	82-86	
24101442-6	2014	Moreover, the JNK inhibitor SP600125 decreased production of IL-6 and TNF-alpha induced by LDH.	pyrazolanthrone	28-36	interleukin 6	Mus musculus	61-65	
25004880-6	2014	The JNK-specific inhibitor SP600125 decreased the proteins expression of phospho-JNK, iNOS, COX-2, and the mRNAs expression and levels of IL-6 and TNF-alpha.	pyrazolanthrone	27-35	interleukin 6	Mus musculus	138-142	
20609399-7	2010	SD-0006 or SP600125, a JNK inhibitor, partially blocked the elevation of IL-6 production in RASF following stimulation with TNF-alpha.	pyrazolanthrone	11-19	interleukin 6	Mus musculus	73-77	
19299915-4	2009	Inhibition of JNK by the JNK inhibitor SP600125 induced MMP-9 in the absence of serum and suppressed the expression of TNF-alpha, IL-6 and cyclooxygenase-2 in LPS-treated Raw 264.7 cells.	pyrazolanthrone	39-47	interleukin 6	Mus musculus	130-134	
19577630-6	2010	We found that SP600125 blocked JNK phosphorylation and significantly decreased IDO expression induced by LPS, which was accompanied by a reduction of LPS-induced expression of TNFalpha and IL-6.	pyrazolanthrone	14-22	interleukin 6	Mus musculus	189-193	
19954621-9	2009	(4) SB203580 and SP600125 down-regulated allogeneic T lymphocytes-induced VCAM-1, TNF-alpha, IFN-gamma, IL-6 expression in HUVECs.	pyrazolanthrone	17-25	interleukin 6	Mus musculus	104-108	
17460151-7	2007	SP600125 modulated the expression of a subset of 29 ozone-induced genes; IL-6 and CCL2 expression were further increased, whereas the expression of metallothionein 1, hemopexin, and mitogen-activated 3 kinase 6 was decreased in SP600125-treated ozone-exposed mice.	pyrazolanthrone	0-8	interleukin 6	Mus musculus	73-77	
12842862-10	2003	SP-600125 blocked LPS-stimulated IL-6 synthesis dose dependently at both the RNA and protein level.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	33-37	
12842862-11	2003	SP-600125 was as effective as the synthetic glucocorticoid dexamethasone at inhibiting IL-6 expression.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	87-91	
12842862-12	2003	SP-600125 inhibited IL-6 synthesis when added to cells up to 60 min after LPS stimulation, but its inhibitory effect waned with time.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	20-24	
12842862-15	2003	Yet, only SP-600125 and not MG-132 blocked LPS-induced IL-6 mRNA expression.	pyrazolanthrone	10-19	interleukin 6	Mus musculus	55-59	
32567086-10	2021	Inhibitors of MEK1/2 (PD98059), JNK (SP600125), upstream kinase of p70 S6 kinase (rapamycin) and Akt (deguelin), all increased IL-6 release.	pyrazolanthrone	37-45	interleukin 6	Mus musculus	127-131	
14722032-9	2004	SP-600125 (a JNK inhibitor) and SB-202190 (a p38 MAP kinase inhibitor) completely blocked epinephrine-induced IL-6 synthesis.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	110-114